Amy Turner, Ph.D. from the University of Leeds, The Astbury Centre, Tomlinsonlab@leeds speaks about New treatment approach targets cancer ‘Death Star’.
Link to Article:
https://healthcare-in-europe.com/en/news/new-treatment-approach-targets-cancer-death-star.html
Because of its capacity to withstand therapies, the mutant version of the RAS protein has been dubbed the “Death Star,” and it is present in 96 percent of pancreatic tumors and 54 percent of colorectal cancers. RAS is a vital protein for health, but it may be turned on for longer in its mutant version, leading to tumor development. Although one medication has been licensed for use, it can only treat a tiny portion of the overall number of malignancies caused by RAS. Now, researchers at the University’s School of Molecular and Cellular Biology have discovered a novel approach to target the protein, opening the door to a wider spectrum of therapies for more patients.
The findings were reported in Nature Communications by the researchers.
Although work on developing other methods to target RAS is still in its early stages, the researchers hope their discovery might lead to novel therapies, placing Leeds at the forefront of the cancer battle.